Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J. Dore, Thomas Podsadecki, Adrian Streinu‐Cercel et al.|Journal of Hepatology|2015Cited by 68
60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTIONMark Sulkowski, Gerhard Steinmann, E. Ceasu et al.|Journal of Hepatology|2011Cited by 39
66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/RMark Sulkowski, Gerhard Steinmann, Marc Bourlière et al.|Journal of Hepatology|2011Cited by 30